date
date32
stock
stringclasses
98 values
title
stringlengths
13
158
content
stringlengths
2
15k
trading_date
timestamp[ns]
exact_trading_date
timestamp[ns]
ts_-30
float64
0.23
2.5k
ts_-29
float64
0.22
2.62k
ts_-28
float64
0.22
2.64k
ts_-27
float64
0.23
2.65k
ts_-26
float64
0.23
2.65k
ts_-25
float64
0.23
2.57k
ts_-24
float64
0.23
2.48k
ts_-23
float64
0.25
2.48k
ts_-22
float64
0.25
2.51k
ts_-21
float64
0.25
2.62k
ts_-20
float64
0.24
2.64k
ts_-19
float64
0.25
2.65k
ts_-18
float64
0.25
2.62k
ts_-17
float64
0.25
2.64k
ts_-16
float64
0.24
2.65k
ts_-15
float64
0.23
2.64k
ts_-14
float64
0.24
2.65k
ts_-13
float64
0.24
2.62k
ts_-12
float64
0.23
2.64k
ts_-11
float64
0.23
2.65k
ts_-10
float64
0.23
2.57k
ts_-9
float64
0.22
2.48k
ts_-8
float64
0.22
2.49k
ts_-7
float64
0.23
2.48k
ts_-6
float64
0.24
2.51k
ts_-5
float64
0.23
2.51k
ts_-4
float64
0.23
2.62k
ts_-3
float64
0.22
2.64k
ts_-2
float64
0.22
2.65k
ts_-1
float64
0.22
2.57k
ts_0
float64
0.23
2.48k
ts_1
float64
0.23
2.62k
ts_2
float64
0.23
2.64k
ts_3
float64
0.23
2.65k
ts_4
float64
0.22
2.65k
ts_5
float64
0.22
2.57k
ts_6
float64
0.23
2.48k
ts_7
float64
0.23
2.46k
ts_8
float64
0.23
2.5k
ts_9
float64
0.23
2.54k
ts_10
float64
0.23
2.51k
ts_11
float64
0.22
2.5k
ts_12
float64
0.22
2.48k
ts_13
float64
0.23
2.44k
ts_14
float64
0.23
2.48k
ts_15
float64
0.23
2.46k
2020-03-11
VRSK
Verisk Analytics goes ex-dividend tomorrow
Verisk Analytics (NASDAQ:VRSK) had declared $0.27/share quarterly dividend, 8% increase from prior dividend of $0.25. Payable March 31; for shareholders of record March 13; ex-div March 12. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2020-03-12T00:00:00
2020-03-12T00:00:00
164.179993
164.710007
162.470001
165.220001
168.130005
168.559998
168.949997
169.119995
169.940002
167.889999
169.279999
170.669998
171.380005
171.559998
169.740005
169.389999
168.690002
167.580002
162.820007
163.529999
155.789993
155.110001
163.130005
160.399994
169.179993
164.970001
163.369995
147.919998
156.740005
151.679993
139.490005
145.610001
130.059998
144.710007
135.110001
136.479996
124.25
121.18
137.279999
134.300003
142.100006
137.770004
146.869995
139.380005
140.779999
142.990005
2020-05-04
VRSK
Verisk Analytics Q1 2020 Earnings Preview
Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q1 earnings results on Tuesday, May 5th, after market close. The consensus EPS Estimate is $1.13 (+9.7% Y/Y) and the consensus Revenue Estimate is $677.79M (+8.4% Y/Y). Over the last 2 years, VRSK has beaten EPS estimates 38% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 2 upward revisions and 5 downward. Revenue estimates have seen 0 upward revisions and 4 downward.
2020-05-05T00:00:00
2020-05-05T00:00:00
121.18
137.279999
134.300003
142.100006
137.770004
146.869995
139.380005
140.779999
142.990005
141.649994
147.740005
147.169998
148.699997
148.259995
144.160004
150.300003
147.130005
149.110001
153.789993
149.320007
145.210007
151.199997
147.699997
148.539993
151.800003
151.789993
153.070007
152.830002
153.449997
154.460007
157.490005
155.179993
158.270004
159.570007
160.710007
156.600006
154.429993
153.899994
154.559998
158.320007
158.059998
159.539993
156.839996
157.279999
160.460007
163.460007
2020-05-05
VRSK
Verisk Analytics declares $0.27 dividend
Verisk Analytics (NASDAQ:VRSK) declares $0.27/share quarterly dividend, in line with previous. Forward yield 0.69% Payable June 30; for shareholders of record June 15; ex-div June 12. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2020-05-06T00:00:00
2020-05-06T00:00:00
137.279999
134.300003
142.100006
137.770004
146.869995
139.380005
140.779999
142.990005
141.649994
147.740005
147.169998
148.699997
148.259995
144.160004
150.300003
147.130005
149.110001
153.789993
149.320007
145.210007
151.199997
147.699997
148.539993
151.800003
151.789993
153.070007
152.830002
153.449997
154.460007
157.490005
155.179993
158.270004
159.570007
160.710007
156.600006
154.429993
153.899994
154.559998
158.320007
158.059998
159.539993
156.839996
157.279999
160.460007
163.460007
168.339996
2020-05-05
VRSK
Verisk Analytics EPS beats by $0.04, beats on revenue
Verisk Analytics (NASDAQ:VRSK): Q1 Non-GAAP EPS of $1.17 beats by $0.04; GAAP EPS of $1.04 beats by $0.12. Revenue of $689.8M (+10.4% Y/Y) beats by $12.01M. Press Release
2020-05-06T00:00:00
2020-05-06T00:00:00
137.279999
134.300003
142.100006
137.770004
146.869995
139.380005
140.779999
142.990005
141.649994
147.740005
147.169998
148.699997
148.259995
144.160004
150.300003
147.130005
149.110001
153.789993
149.320007
145.210007
151.199997
147.699997
148.539993
151.800003
151.789993
153.070007
152.830002
153.449997
154.460007
157.490005
155.179993
158.270004
159.570007
160.710007
156.600006
154.429993
153.899994
154.559998
158.320007
158.059998
159.539993
156.839996
157.279999
160.460007
163.460007
168.339996
2020-08-03
VRSK
Verisk Analytics Q2 2020 Earnings Preview
Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q2 earnings results on Tuesday, August 4th, after market close. The consensus EPS Estimate is $1.19 (+8.2% Y/Y) and the consensus Revenue Estimate is $685.84M (+5.1% Y/Y). Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 4 upward revisions and 11 downward. Revenue estimates have seen 1 upward revision and 11 downward.
2020-08-04T00:00:00
2020-08-04T00:00:00
167.270004
166.809998
163.690002
166.210007
162.889999
164.339996
170.199997
172.419998
173.110001
173.559998
172.929993
172.830002
173.199997
174.169998
172.850006
174.589996
175.399994
175.419998
178.399994
181.600006
180.679993
181.350006
180.630005
179.779999
183.210007
182.429993
187.649994
187.169998
188.710007
186.960007
187.720001
186.660004
189.559998
191.160004
189.649994
187.889999
190.429993
190.710007
189.149994
189.070007
189.130005
187.240005
185.860001
185.649994
185.110001
185.970001
2020-08-04
VRSK
Verisk Analytics EPS beats by $0.10, misses on revenue
Verisk Analytics (NASDAQ:VRSK): Q2 Non-GAAP EPS of $1.29 beats by $0.10; GAAP EPS of $1.08 beats by $0.10. Revenue of $678.8M (+4.0% Y/Y) misses by $7.04M. Shares -0.31%. Press Release
2020-08-05T00:00:00
2020-08-05T00:00:00
166.809998
163.690002
166.210007
162.889999
164.339996
170.199997
172.419998
173.110001
173.559998
172.929993
172.830002
173.199997
174.169998
172.850006
174.589996
175.399994
175.419998
178.399994
181.600006
180.679993
181.350006
180.630005
179.779999
183.210007
182.429993
187.649994
187.169998
188.710007
186.960007
187.720001
186.660004
189.559998
191.160004
189.649994
187.889999
190.429993
190.710007
189.149994
189.070007
189.130005
187.240005
185.860001
185.649994
185.110001
185.970001
186.410004
2020-09-11
VRSK
Verisk acquires Franco Signor for $160M
Verisk  (NASDAQ:VRSK) acquires Franco Signor, a highly-regarded medicare secondary payer service provider. Franco Signor will become part of the Verisk's Claims Partner business, a leading provider of MSP compliance and other analytic claim services. Purchase price was $160M Claims Partners and Franco Signor will be combining forces to provide the single best resource for Medicare compliance. “We anticipate that this acquisition will have substantive long-term advantages for the industry, as Verisk will now be able to offer unparalleled guidance and an all-inclusive solution suite for all aspects of an insurer’s Medicare compliance needs.” said Mark Anquillare, COO. Take a brief look at the company's growing figures here.
2020-09-12T00:00:00
2020-09-14T00:00:00
188.710007
186.960007
187.720001
186.660004
189.559998
191.160004
189.649994
187.889999
190.429993
190.710007
189.149994
189.070007
189.130005
187.240005
185.860001
185.649994
185.110001
185.970001
186.410004
186.610001
187.350006
186.669998
187.690002
192.789993
187.279999
182.770004
178.089996
182.960007
181.5
181.639999
185.080002
187.839996
186.789993
184.789993
181.580002
178.679993
180.389999
177.080002
177.229996
181.339996
184.520004
184.380005
185.309998
185.639999
182.100006
181.789993
2020-09-11
VRSK
Verisk Analytics goes ex-dividend on Monday
Verisk Analytics (NASDAQ:VRSK) had declared $0.27/share quarterly dividend, in line with previous. Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2020-09-12T00:00:00
2020-09-14T00:00:00
188.710007
186.960007
187.720001
186.660004
189.559998
191.160004
189.649994
187.889999
190.429993
190.710007
189.149994
189.070007
189.130005
187.240005
185.860001
185.649994
185.110001
185.970001
186.410004
186.610001
187.350006
186.669998
187.690002
192.789993
187.279999
182.770004
178.089996
182.960007
181.5
181.639999
185.080002
187.839996
186.789993
184.789993
181.580002
178.679993
180.389999
177.080002
177.229996
181.339996
184.520004
184.380005
185.309998
185.639999
182.100006
181.789993
2020-09-22
VRSK
AIR Worldwide launched updated Multiple Peril Crop Insurance for China
Catastrophe risk modeling firm AIR Worldwide (AIR), a Verisk (NASDAQ:VRSK) business, released an updated Multiple Peril Crop Insurance (MPCI) Model for China to support probabilistic assessments for five newly modeled crop lines of business and a newly modeled sub-peril. This update also includes a new livestock module that adds six additional lines of business and two new sub-perils. Dr. Jeff Amthor, assistant vice president, AIR Worldwide, said, “The MPCI Model for China captures the severity, frequency, and location of drought, flood, wind, frost, and heat events nationwide, covering over 90% of the weather-related crop losses.”
2020-09-23T00:00:00
2020-09-23T00:00:00
187.889999
190.429993
190.710007
189.149994
189.070007
189.130005
187.240005
185.860001
185.649994
185.110001
185.970001
186.410004
186.610001
187.350006
186.669998
187.690002
192.789993
187.279999
182.770004
178.089996
182.960007
181.5
181.639999
185.080002
187.839996
186.789993
184.789993
181.580002
178.679993
180.389999
177.080002
177.229996
181.339996
184.520004
184.380005
185.309998
185.639999
182.100006
181.789993
179.789993
183.029999
184.899994
187.179993
192.75
193.649994
191.759995
2020-10-13
VRSK
Ford and Verisk Analytics join hands to offer telematics data to insurers
Verisk (VRSK +0.5%) announces that Ford Motor Company (F -0.1%) has joined the Verisk Data Exchange. Owners of eligible Ford and Lincoln vehicles will soon have easy access to usage-based insurance programs from the many U.S. auto insurers that connect to the Exchange—including three of the ten largest U.S. carriers. Usage-based insurance can give drivers greater transparency and control over their insurance costs. “Ford is committed to connecting our customers to valuable services that can help them reduce their total cost of ownership and get more out of their Ford vehicle — usage-based insurance is a great opportunity to do that,” said Alex Purdy, director of business operations, enterprise connectivity, Ford Motor Company.
2020-10-14T00:00:00
2020-10-14T00:00:00
187.690002
192.789993
187.279999
182.770004
178.089996
182.960007
181.5
181.639999
185.080002
187.839996
186.789993
184.789993
181.580002
178.679993
180.389999
177.080002
177.229996
181.339996
184.520004
184.380005
185.309998
185.639999
182.100006
181.789993
179.789993
183.029999
184.899994
187.179993
192.75
193.649994
191.759995
192.020004
192.470001
188.5
190.360001
189.179993
188.880005
189.25
185.490005
185.149994
179.490005
179.220001
177.970001
182.149994
187.949997
196.389999
2020-10-14
VRSK
AIR Worldwide estimates $1-$3B insured losses for Hurricane Delta
Catastrophe risk modeling firm AIR Worldwide, a Verisk (NASDAQ:VRSK) business, estimates industry insured losses to onshore property resulting from Hurricane Delta's winds and storm surge will range from $1 to $3B. Included in AIR's estimates are losses to onshore residential, commercial, and industrial properties and automobiles for their building, contents, and time element coverage.
2020-10-15T00:00:00
2020-10-15T00:00:00
192.789993
187.279999
182.770004
178.089996
182.960007
181.5
181.639999
185.080002
187.839996
186.789993
184.789993
181.580002
178.679993
180.389999
177.080002
177.229996
181.339996
184.520004
184.380005
185.309998
185.639999
182.100006
181.789993
179.789993
183.029999
184.899994
187.179993
192.75
193.649994
191.759995
192.020004
192.470001
188.5
190.360001
189.179993
188.880005
189.25
185.490005
185.149994
179.490005
179.220001
177.970001
182.149994
187.949997
196.389999
194.410004
2020-11-03
VRSK
Verisk Analytics Q3 2020 Earnings Preview
Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q3 earnings results on Wednesday, November 4th, after market close. The consensus EPS Estimate is $1.20 (+7.1% Y/Y) and the consensus Revenue Estimate is $692.14M (+6.0% Y/Y). Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 88% of the time. Over the last 3 months, EPS estimates have seen 7 upward revisions and 8 downward. Revenue estimates have seen 5 upward revisions and 9 downward.
2020-11-04T00:00:00
2020-11-04T00:00:00
177.080002
177.229996
181.339996
184.520004
184.380005
185.309998
185.639999
182.100006
181.789993
179.789993
183.029999
184.899994
187.179993
192.75
193.649994
191.759995
192.020004
192.470001
188.5
190.360001
189.179993
188.880005
189.25
185.490005
185.149994
179.490005
179.220001
177.970001
182.149994
187.949997
196.389999
194.410004
197.350006
196.309998
195.100006
199.830002
199.179993
203.699997
205.25
205.279999
203.899994
205.720001
204.369995
198.119995
194.479996
195.619995
2020-11-04
VRSK
Verisk Analytics EPS beats by $0.12, beats on revenue
Verisk Analytics (NASDAQ:VRSK): Q3 Non-GAAP EPS of $1.32 beats by $0.12; GAAP EPS of $1.12 beats by $0.17. Revenue of $702.7M (+7.7% Y/Y) beats by $10.56M. Press Release
2020-11-05T00:00:00
2020-11-05T00:00:00
177.229996
181.339996
184.520004
184.380005
185.309998
185.639999
182.100006
181.789993
179.789993
183.029999
184.899994
187.179993
192.75
193.649994
191.759995
192.020004
192.470001
188.5
190.360001
189.179993
188.880005
189.25
185.490005
185.149994
179.490005
179.220001
177.970001
182.149994
187.949997
196.389999
194.410004
197.350006
196.309998
195.100006
199.830002
199.179993
203.699997
205.25
205.279999
203.899994
205.720001
204.369995
198.119995
194.479996
195.619995
198.229996
2020-11-30
VRSK
S&P Global all-stock $44B deal undervalues IHS Markit, Truist analyst says
S&P Global's (NYSE:SPGI) agreement to buy IHS Markit (NYSE:INFO) at ~$44B enterprise value, or $98 per share in stock, materially undervalues INFO, according to Truist analyst Andrew Jeffrey. The ~6% premium to INFO's recent close is disappointing when considering IHS's multi-year organic revenue, EBITDA, and free cash flow compounding outlook, the analyst wrote in a note to clients The combined entity's expected 6.5%-8% CY22-23 organic revenue growth outlook is "materially comparable to IHS's stand-alone outlook" and "highlights what we view as the dubious merits of the combination," Jeffrey said. Points out that the proposed merger would value INFO at ~21.7x CY21E EBITDA, which is an about 11% discount to info services rival Verisk (NASDAQ:VRSK), he adds. Jeffrey also finds it surprising that Markit's founder and current IHS Markit CEO Lance Uggla won't hold a leadership role in the combined SPGI/INFO. "We are startled by this outcome given his entrepreneurial roots and the success he has achieved as IHS' CEO," Jeffrey said. "Little about this transaction makes sense to us." He also doesn't see an rival suitors stepping up as the size of the transaction makes it prohibitive for private equity. IHS Markit is up 6.9% in premarket trading, bringing the stock's price to $98.95. See IHS Markit's enterprise value/EBITDA vs. S&P Global and Verisk over the past five years: See how INFO's Quant factor grades stack up against SPGI, Verisk, and FactSet:
2020-12-01T00:00:00
2020-12-01T00:00:00
188.5
190.360001
189.179993
188.880005
189.25
185.490005
185.149994
179.490005
179.220001
177.970001
182.149994
187.949997
196.389999
194.410004
197.350006
196.309998
195.100006
199.830002
199.179993
203.699997
205.25
205.279999
203.899994
205.720001
204.369995
198.119995
194.479996
195.619995
198.229996
198.309998
200.139999
195.990005
193.850006
195.679993
194.449997
194.929993
193.449997
192.199997
193.990005
194.770004
196.139999
195.880005
201.240005
204.470001
202.770004
201.929993
2020-12-11
VRSK
Verisk Analytics goes ex-dividend on Monday
Verisk Analytics (NASDAQ:VRSK) had declared $0.27/share quarterly dividend, in line with previous. Payable Dec. 31; for shareholders of record Dec. 15; ex-div Dec. 14. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2020-12-12T00:00:00
2020-12-14T00:00:00
177.970001
182.149994
187.949997
196.389999
194.410004
197.350006
196.309998
195.100006
199.830002
199.179993
203.699997
205.25
205.279999
203.899994
205.720001
204.369995
198.119995
194.479996
195.619995
198.229996
198.309998
200.139999
195.990005
193.850006
195.679993
194.449997
194.929993
193.449997
192.199997
193.990005
194.770004
196.139999
195.880005
201.240005
204.470001
202.770004
201.929993
199.970001
201.229996
207.979996
205.669998
205.779999
207.589996
202.880005
201.970001
200.059998
2020-12-15
VRSK
Verisk to acquire consumer behavioral data and intelligence firm, Jornaya
Verisk (NASDAQ:VRSK) inks agreement to acquire Jornaya, a leading provider of consumer behavioral data and intelligence. The acquisition will add Jornaya's proprietary view of consumer buying journeys to Verisk's marketing solutions for the insurance and financial services markets. With this acquisition, VRSK clients will have the intelligence and agility to time and tailor interactions based on actual in-market behaviors. Financial terms weren't disclosed
2020-12-16T00:00:00
2020-12-16T00:00:00
187.949997
196.389999
194.410004
197.350006
196.309998
195.100006
199.830002
199.179993
203.699997
205.25
205.279999
203.899994
205.720001
204.369995
198.119995
194.479996
195.619995
198.229996
198.309998
200.139999
195.990005
193.850006
195.679993
194.449997
194.929993
193.449997
192.199997
193.990005
194.770004
196.139999
195.880005
201.240005
204.470001
202.770004
201.929993
199.970001
201.229996
207.979996
205.669998
205.779999
207.589996
202.880005
201.970001
200.059998
200.970001
200.899994
2021-02-01
VRSK
Enigma Technologies collaborates with Verisk Financial
Verisk Financial (VRSK +1.7%) and Enigma Technologies announce a strategic collaboration. Enigma Technologies, a data science company that collects and analyzes information on the health and identity of every U.S. business. Through the Verisk collaboration, Enigma is launching a new solution that allows clients to see and understand how small business revenues are trending in near real-time. Combining these revenue trends with Enigma's proprietary entity resolution and machine learning techniques provides actionable estimates about the financial health of more than 20M small businesses. These insights enable risk, underwriting, and marketing teams at financial institutions to better segment and serve small businesses. Enigma to joins a consortium of banks, payments processors, and financial institutions to provide trustworthy intelligence about a small business's financial health.
2021-02-02T00:00:00
2021-02-02T00:00:00
201.240005
204.470001
202.770004
201.929993
199.970001
201.229996
207.979996
205.669998
205.779999
207.589996
202.880005
201.970001
200.059998
200.970001
200.899994
197.869995
196.639999
196.880005
193.880005
190.020004
191.369995
194.710007
194.869995
192.759995
188.679993
188.5
184.270004
186.429993
183.5
185.940002
188.699997
186.869995
188.389999
187.429993
188.860001
190.509995
190.820007
189.300003
189.5
188.360001
188.559998
192.020004
190.490005
186.240005
185.360001
167.529999
2021-02-22
VRSK
Verisk Analytics Q4 2020 Earnings Preview
Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q4 earnings results on Tuesday, February 23rd, after market close. The consensus EPS Estimate is $1.30 (+15.0% Y/Y) and the consensus Revenue Estimate is $717.04M (+5.9% Y/Y). Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 88% of the time. Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 2 upward revisions and 0 downward.
2021-02-23T00:00:00
2021-02-23T00:00:00
200.899994
197.869995
196.639999
196.880005
193.880005
190.020004
191.369995
194.710007
194.869995
192.759995
188.679993
188.5
184.270004
186.429993
183.5
185.940002
188.699997
186.869995
188.389999
187.429993
188.860001
190.509995
190.820007
189.300003
189.5
188.360001
188.559998
192.020004
190.490005
186.240005
185.360001
167.529999
164.289993
163.850006
167.039993
166.380005
164.809998
161.649994
168.119995
171.649994
174.419998
174.860001
173.210007
171.759995
174.589996
172.970001
2021-02-23
VRSK
Verisk Analytics raises dividend by 7% to $0.29
Verisk Analytics (NASDAQ:VRSK) declares $0.29/share quarterly dividend, 7.4% increase from prior dividend of $0.27. Forward yield 0.63% Payable March 31; for shareholders of record March 15; ex-div March 12. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2021-02-24T00:00:00
2021-02-24T00:00:00
197.869995
196.639999
196.880005
193.880005
190.020004
191.369995
194.710007
194.869995
192.759995
188.679993
188.5
184.270004
186.429993
183.5
185.940002
188.699997
186.869995
188.389999
187.429993
188.860001
190.509995
190.820007
189.300003
189.5
188.360001
188.559998
192.020004
190.490005
186.240005
185.360001
167.529999
164.289993
163.850006
167.039993
166.380005
164.809998
161.649994
168.119995
171.649994
174.419998
174.860001
173.210007
171.759995
174.589996
172.970001
171.940002
2021-02-23
VRSK
Verisk Analytics EPS misses by $0.03, misses on revenue
Verisk Analytics (NASDAQ:VRSK): Q4 Non-GAAP EPS of $1.27 misses by $0.03; GAAP EPS of $1.07 misses by $0.01. Revenue of $713.3M (+5.4% Y/Y) misses by $3.74M. Press Release
2021-02-24T00:00:00
2021-02-24T00:00:00
197.869995
196.639999
196.880005
193.880005
190.020004
191.369995
194.710007
194.869995
192.759995
188.679993
188.5
184.270004
186.429993
183.5
185.940002
188.699997
186.869995
188.389999
187.429993
188.860001
190.509995
190.820007
189.300003
189.5
188.360001
188.559998
192.020004
190.490005
186.240005
185.360001
167.529999
164.289993
163.850006
167.039993
166.380005
164.809998
161.649994
168.119995
171.649994
174.419998
174.860001
173.210007
171.759995
174.589996
172.970001
171.940002
2021-03-08
VRSK
Verisk upgraded at Deutsche Bank on 'attractive buying opportunity'
Citing the recent pullback, Deutsche Bank upgrades Verisk Analytics (NASDAQ:VRSK) from Hold to Buy with a $196 price target, implying a 17% upside. Analyst Ashish Sabadra sees an "attractive buying opportunity" ahead of revenue growth improvement, driven by sustained subscription revenue and transaction revenue recovering from its pandemic hit. The analyst also praises Verisk's "commanding market position in defensive end markets" and tailwinds from the secular digitization trends. Verisk shares are up 1% pre-market to $169.76. VRSK is down over 10% in the past month since the company reported Q4 revenue and EPS misses.
2021-03-09T00:00:00
2021-03-09T00:00:00
188.679993
188.5
184.270004
186.429993
183.5
185.940002
188.699997
186.869995
188.389999
187.429993
188.860001
190.509995
190.820007
189.300003
189.5
188.360001
188.559998
192.020004
190.490005
186.240005
185.360001
167.529999
164.289993
163.850006
167.039993
166.380005
164.809998
161.649994
168.119995
171.649994
174.419998
174.860001
173.210007
171.759995
174.589996
172.970001
171.940002
170.550003
171.869995
174.820007
177.589996
176.929993
174.779999
178.630005
180.320007
175.949997
2021-03-16
VRSK
Verisk expands into group life insurance market by acquiring assets and capabilities of 4C Solutions
FAST, a Verisk (VRSK -0.1%) business is acquiring assets and capabilities of 4C Solutions, a software advisory firm in group life insurance. Transaction terms not dislcosed. The acquisition will help insurers meet the rapidly changing coverage needs of companies and their employees. "Managing group life insurance can be a major challenge for insurers, many of whom rely on decades-old technology to help employees obtain the coverage they need," said Tom Famularo, managing director and co-founder of FAST. "The addition of 4C’s capabilities will help us serve the group life market. Our scalable, no-code solutions can be implemented in months and will provide group insurers with tools to improve operational efficiency and transform the customer experience."
2021-03-17T00:00:00
2021-03-17T00:00:00
188.699997
186.869995
188.389999
187.429993
188.860001
190.509995
190.820007
189.300003
189.5
188.360001
188.559998
192.020004
190.490005
186.240005
185.360001
167.529999
164.289993
163.850006
167.039993
166.380005
164.809998
161.649994
168.119995
171.649994
174.419998
174.860001
173.210007
171.759995
174.589996
172.970001
171.940002
170.550003
171.869995
174.820007
177.589996
176.929993
174.779999
178.630005
180.320007
175.949997
176.690002
179.809998
181.550003
180.889999
179.990005
181.210007
2021-04-20
VRSK
Archegos co-founder Mills resigns from Verisk Analytics board
Verisk Analytics (NASDAQ:VRSK) announces the resignation of board director Andrew G. Mills, effective April 18. Mills joined the board in 2002. Mills was the executive chairman and co-CEO of Archegos Capital Management, the family office of Bill Hwang that imploded, causing damage to lenders like Credit Suisse.Â
2021-04-21T00:00:00
2021-04-21T00:00:00
174.419998
174.860001
173.210007
171.759995
174.589996
172.970001
171.940002
170.550003
171.869995
174.820007
177.589996
176.929993
174.779999
178.630005
180.320007
175.949997
176.690002
179.809998
181.550003
180.889999
179.990005
181.210007
182.699997
182.5
183.570007
181.949997
184.5
185.460007
184.529999
184.440002
185.380005
187.259995
188.880005
186.470001
187.199997
187.259995
188.600006
188.199997
188.550003
188.520004
172.630005
175.020004
178.770004
179.559998
175.080002
172
2021-05-03
VRSK
Verisk Analytics Q1 2021 Earnings Preview
Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q1 earnings results on Tuesday, May 4th, after market close. The consensus EPS Estimate is $1.25 (+6.8% Y/Y) and the consensus Revenue Estimate is $726.5M (+5.3% Y/Y). Analysts expect adjusted EBITDA of $347.5M with adjusted EBITDA margin of 47.9%. Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 4 upward revisions and 7 downward. Revenue estimates have seen 3 upward revisions and 5 downward.
2021-05-04T00:00:00
2021-05-04T00:00:00
174.820007
177.589996
176.929993
174.779999
178.630005
180.320007
175.949997
176.690002
179.809998
181.550003
180.889999
179.990005
181.210007
182.699997
182.5
183.570007
181.949997
184.5
185.460007
184.529999
184.440002
185.380005
187.259995
188.880005
186.470001
187.199997
187.259995
188.600006
188.199997
188.550003
188.520004
172.630005
175.020004
178.770004
179.559998
175.080002
172
173.580002
175
172.940002
172.059998
173.070007
173.350006
173.509995
174.169998
173.699997
2021-05-04
VRSK
Verisk Analytics declares $0.29 dividend
Verisk Analytics (NASDAQ:VRSK) declares $0.29/share quarterly dividend, in line with previous. Forward yield 0.62% Payable June 30; for shareholders of record June 15; ex-div June 14. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2021-05-05T00:00:00
2021-05-05T00:00:00
177.589996
176.929993
174.779999
178.630005
180.320007
175.949997
176.690002
179.809998
181.550003
180.889999
179.990005
181.210007
182.699997
182.5
183.570007
181.949997
184.5
185.460007
184.529999
184.440002
185.380005
187.259995
188.880005
186.470001
187.199997
187.259995
188.600006
188.199997
188.550003
188.520004
172.630005
175.020004
178.770004
179.559998
175.080002
172
173.580002
175
172.940002
172.059998
173.070007
173.350006
173.509995
174.169998
173.699997
172.979996
2021-05-04
VRSK
Verisk Analytics EPS misses by $0.02, revenue in-line
Verisk Analytics (NASDAQ:VRSK): Q1 Non-GAAP EPS of $1.23 misses by $0.02; GAAP EPS of $1.03 misses by $0.02. Revenue of $726.1M (+5.3% Y/Y) in-line. Press Release
2021-05-05T00:00:00
2021-05-05T00:00:00
177.589996
176.929993
174.779999
178.630005
180.320007
175.949997
176.690002
179.809998
181.550003
180.889999
179.990005
181.210007
182.699997
182.5
183.570007
181.949997
184.5
185.460007
184.529999
184.440002
185.380005
187.259995
188.880005
186.470001
187.199997
187.259995
188.600006
188.199997
188.550003
188.520004
172.630005
175.020004
178.770004
179.559998
175.080002
172
173.580002
175
172.940002
172.059998
173.070007
173.350006
173.509995
174.169998
173.699997
172.979996
2021-06-18
VRSK
Wood Mackenzie expands energy transition expertise with the acquisition of Roskill
Wood Mackenzie, a Verisk (NASDAQ:VRSK) business, acquires Roskill, a privately-owned company and leader in metals and materials supply chain intelligence. The commercial terms were not disclosed. Neal Anderson, President of Wood Mackenzie: “..In particular, Roskill adds market-leading analysis, data, and insight on battery raw materials metals, which are an integral component of the energy transition.” In addition, the Company also announces that Valerie Purvis will be assuming the role of Global Head of Metals & Mining, including Roskill. This appointment is in addition to Valerie's current responsibility as Global Head of the Chemicals business. Press Release
2021-06-19T00:00:00
2021-06-21T00:00:00
178.770004
179.559998
175.080002
172
173.580002
175
172.940002
172.059998
173.070007
173.350006
173.509995
174.169998
173.699997
172.979996
172.130005
172.830002
171.179993
172.679993
171.830002
172.649994
167.800003
169.5
169.919998
170.820007
172.199997
173.270004
172.570007
170.899994
172.990005
171.089996
174.910004
175.259995
171.699997
173.309998
174.699997
173.979996
174.330002
174.720001
176.800003
177.5
177.610001
182.089996
181.210007
181.710007
180.020004
181.169998
2021-06-22
VRSK
Verisk business launches first-of-its-kind refinery intelligence tool
Wood Mackenzie, a Verisk business (NASDAQ:VRSK), is now offering Refinery I/O, a new tool providing daily refinery analytics from proprietary data sets. The new tool will deliver more than 1,020 data points to users every day via API, along with weekly summary reports and supplemental analysis on significant events, such as weather incidents like hurricane season and Covid-19 developments, as they affect the U.S. and Canadian refineries. “With its operational efficiencies, not only does this product provide refinery-level granularity, which serves multiple client use cases, but it saves time analyzing internal processes.” Press Release
2021-06-23T00:00:00
2021-06-23T00:00:00
175.080002
172
173.580002
175
172.940002
172.059998
173.070007
173.350006
173.509995
174.169998
173.699997
172.979996
172.130005
172.830002
171.179993
172.679993
171.830002
172.649994
167.800003
169.5
169.919998
170.820007
172.199997
173.270004
172.570007
170.899994
172.990005
171.089996
174.910004
175.259995
171.699997
173.309998
174.699997
173.979996
174.330002
174.720001
176.800003
177.5
177.610001
182.089996
181.210007
181.710007
180.020004
181.169998
182.330002
184.759995
2021-08-02
VRSK
Verisk Analytics Q2 2021 Earnings Preview
Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q2 earnings results on Tuesday, August 3rd, after market close. The consensus EPS Estimate is $1.33 (+3.1% Y/Y) and the consensus Revenue Estimate is $737.58M (+8.7% Y/Y). Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 4 upward revisions and 7 downward. Revenue estimates have seen 6 upward revisions and 4 downward.
2021-08-03T00:00:00
2021-08-03T00:00:00
174.910004
175.259995
171.699997
173.309998
174.699997
173.979996
174.330002
174.720001
176.800003
177.5
177.610001
182.089996
181.210007
181.710007
180.020004
181.169998
182.330002
184.759995
186.990005
184.309998
187.429993
187.089996
187.199997
188.389999
186.820007
186.699997
185.270004
187.809998
189.940002
190
188.490005
187.479996
189.910004
188.130005
187.460007
187.5
190.369995
190.130005
191.240005
191.399994
193
190.759995
194.679993
196.389999
197.509995
197.169998
2021-08-03
VRSK
Verisk Analytics declares $0.29 dividend
Verisk Analytics (NASDAQ:VRSK) declares $0.29/share quarterly dividend, in line with previous. Forward yield 0.62% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2021-08-04T00:00:00
2021-08-04T00:00:00
175.259995
171.699997
173.309998
174.699997
173.979996
174.330002
174.720001
176.800003
177.5
177.610001
182.089996
181.210007
181.710007
180.020004
181.169998
182.330002
184.759995
186.990005
184.309998
187.429993
187.089996
187.199997
188.389999
186.820007
186.699997
185.270004
187.809998
189.940002
190
188.490005
187.479996
189.910004
188.130005
187.460007
187.5
190.369995
190.130005
191.240005
191.399994
193
190.759995
194.679993
196.389999
197.509995
197.169998
197.820007
2021-08-03
VRSK
Verisk Analytics EPS misses by $0.16, beats on revenue
Verisk Analytics (NASDAQ:VRSK): Q2 Non-GAAP EPS of $1.17 misses by $0.16; GAAP EPS of $0.94 misses by $0.16. Revenue of $747.5M (+10.1% Y/Y) beats by $9.92M. Press Release
2021-08-04T00:00:00
2021-08-04T00:00:00
175.259995
171.699997
173.309998
174.699997
173.979996
174.330002
174.720001
176.800003
177.5
177.610001
182.089996
181.210007
181.710007
180.020004
181.169998
182.330002
184.759995
186.990005
184.309998
187.429993
187.089996
187.199997
188.389999
186.820007
186.699997
185.270004
187.809998
189.940002
190
188.490005
187.479996
189.910004
188.130005
187.460007
187.5
190.369995
190.130005
191.240005
191.399994
193
190.759995
194.679993
196.389999
197.509995
197.169998
197.820007
2021-08-16
VRSK
Verisk picks industry veteran for human resources chief
Verisk (VRSK +0.4%) appointed 30-years industry veteran Sunita Holzer as EVP & chief human resources officer; she has HR leadership experience spans several industries, including those served by Verisk. Recently, Holzer served as EVP & CHRO of Realogy; she also serves on South Jersey Industries board and is a Human Resources Management Department Advisory Board member at Rutgers School of Management and Labor Relations. She succeeds Vince McCarthy, who stepped in a year and a half ago to lead the company’s HR function.
2021-08-17T00:00:00
2021-08-17T00:00:00
177.610001
182.089996
181.210007
181.710007
180.020004
181.169998
182.330002
184.759995
186.990005
184.309998
187.429993
187.089996
187.199997
188.389999
186.820007
186.699997
185.270004
187.809998
189.940002
190
188.490005
187.479996
189.910004
188.130005
187.460007
187.5
190.369995
190.130005
191.240005
191.399994
193
190.759995
194.679993
196.389999
197.509995
197.169998
197.820007
197.779999
199.520004
200.779999
201.759995
203.059998
204.600006
205.080002
203.110001
206.339996
2021-08-19
VRSK
MRS taps Verisk’s voice analytics to screen for tobacco users
Management Research Services (MRS), a life insurance technology provider, is tapping Verisk’s (VRSK +0.2%) proprietary voice analytics for integration into its telephonic medical interviews. MRS will implement Verisk’s Tobacco Usage Propensity Model, which uses machine learning and AI, to analyze audio interviews and flag possible tobacco users. It will then determine if certain applicants need to submit to lab tests to verify their tobacco usage status. Maroun Mourad, president of global underwriting at Verisk, commented on the integration, "Our model supports more straight-through processing, enabling the majority of applicants to avoid traditional testing and help obtain coverage more quickly. It’s truly a win-win situation, since insurers can reduce premium leakage related to tobacco nondisclosure, which may cost the industry more than $10B in lost premiums over the next three years." Verisk’s Tobacco Usage Propensity Model is part of a suite of advanced analytics, automation and machine learning solutions for life insurance underwriting, claim insights, life and pension analytics, actuarial and portfolio modeling and compliance and fraud detection.
2021-08-20T00:00:00
2021-08-20T00:00:00
181.710007
180.020004
181.169998
182.330002
184.759995
186.990005
184.309998
187.429993
187.089996
187.199997
188.389999
186.820007
186.699997
185.270004
187.809998
189.940002
190
188.490005
187.479996
189.910004
188.130005
187.460007
187.5
190.369995
190.130005
191.240005
191.399994
193
190.759995
194.679993
196.389999
197.509995
197.169998
197.820007
197.779999
199.520004
200.779999
201.759995
203.059998
204.600006
205.080002
203.110001
206.339996
204.860001
205.550003
205.020004
2021-09-13
VRSK
Verisk's AIR estimates up to $30B insured losses from Hurricane Ida
Verisk Analytics' (NASDAQ:VRSK) AIR Worldwide provides insured loss estimates for Hurricane Ida to include impacts of inland flooding across the entirety of its track, including the Northeast. AIR estimates that now its Ida’s insured industry losses will range from $20B to $30B. Wind and storm surge losses are estimated to range from $17B to $25B and private -market insured losses from inland flooding of $2.5B to $5B. The model include insured physical damage to property, additional living expenses, and a 5% leakage, which is assumed to estimate the amount of damage/losses caused by storm surge attributed to wind for residential lines, among other factors. According to AIR and Xactware analyses, "materials costs have gone up significantly in the past year from supply chain disruption in the construction market. Although these costs have moderated since their peak in July when they were 80% higher than September of last year, they remain about 30% higher." Previously (Aug. 19): MRS taps Verisk’s voice analytics to screen for tobacco users
2021-09-14T00:00:00
2021-09-14T00:00:00
190
188.490005
187.479996
189.910004
188.130005
187.460007
187.5
190.369995
190.130005
191.240005
191.399994
193
190.759995
194.679993
196.389999
197.509995
197.169998
197.820007
197.779999
199.520004
200.779999
201.759995
203.059998
204.600006
205.080002
203.110001
206.339996
204.860001
205.550003
205.020004
205.559998
204.559998
202.449997
201.100006
201.699997
202.949997
205.559998
208.970001
207.970001
203.729996
201.740005
202.369995
200.270004
199.990005
198.809998
201.630005
2021-09-29
VRSK
Verisk Analytics enters collaboration with Insurance Regulatory Consultants
We Are/DigitalVision via Getty Images Verisk (NASDAQ:VRSK) and Insurance Regulatory Consultants, a full-service state filing and regulatory compliance company enter into a new collaboration. As part of the collaboration, Verisk to leverage the deep domain expertise and robust data of its ISO business to help new and existing insurers launch new products, improve their actuarial analysis and enhance their strategic decision making. Further, IRC will assist the insurers in the development of these new products and guide them through the regulatory approval process.
2021-09-30T00:00:00
2021-09-30T00:00:00
190.759995
194.679993
196.389999
197.509995
197.169998
197.820007
197.779999
199.520004
200.779999
201.759995
203.059998
204.600006
205.080002
203.110001
206.339996
204.860001
205.550003
205.020004
205.559998
204.559998
202.449997
201.100006
201.699997
202.949997
205.559998
208.970001
207.970001
203.729996
201.740005
202.369995
200.270004
199.990005
198.809998
201.630005
203.729996
206.740005
207.470001
206.529999
207.75
208.369995
211.550003
210.630005
211.039993
212.050003
211.929993
213.139999
2021-11-01
VRSK
Verisk Analytics Q3 2021 Earnings Preview
Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, after market close. The consensus EPS Estimate is $1.36 (+3.0% Y/Y) and the consensus Revenue Estimate is $757.42M (+7.8% Y/Y). Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 14 upward revisions and 0 downward. Revenue estimates have seen 9 upward revisions and 2 downward.
2021-11-02T00:00:00
2021-11-02T00:00:00
202.949997
205.559998
208.970001
207.970001
203.729996
201.740005
202.369995
200.270004
199.990005
198.809998
201.630005
203.729996
206.740005
207.470001
206.529999
207.75
208.369995
211.550003
210.630005
211.039993
212.050003
211.929993
213.139999
213.960007
212.020004
211.320007
207.880005
209.320007
210.270004
208.940002
209.309998
214.289993
216.600006
214.589996
214.910004
216.289993
213.820007
212.990005
216.270004
218.029999
222.600006
224.5
226.720001
230.029999
228.529999
229.320007
2021-11-02
VRSK
Verisk acquires public record data aggregation firm Data Driven Safety
Verisk Analytics (NASDAQ:VRSK) has acquired public record data aggregation firm, Data Driven Safety (DDS). DDS specializes in driver risk assessment. With its unique data collection and management platform, the firm collects information on traffic citations, vehicle accidents and driving records from public sources. It then synthesizes these data to provide insights to help insurers reduce costs, better manage risk and anticipate operational challenges. The acquisition will expand Verisk's auto insurance analytics, providing insurers with information to further refine underwriting, improve the customer experience and promote public safety. Verisk did not acquire the criminal conviction (eLuminateHR.com) or health care cost recovery (MVAreCOUP.com) businesses, which will be owned and operated independently by Safer Public, LLC.
2021-11-03T00:00:00
2021-11-03T00:00:00
205.559998
208.970001
207.970001
203.729996
201.740005
202.369995
200.270004
199.990005
198.809998
201.630005
203.729996
206.740005
207.470001
206.529999
207.75
208.369995
211.550003
210.630005
211.039993
212.050003
211.929993
213.139999
213.960007
212.020004
211.320007
207.880005
209.320007
210.270004
208.940002
209.309998
214.289993
216.600006
214.589996
214.910004
216.289993
213.820007
212.990005
216.270004
218.029999
222.600006
224.5
226.720001
230.029999
228.529999
229.320007
228.210007
2021-11-02
VRSK
Verisk Analytics EPS beats by $0.08, beats on revenue
Verisk Analytics (NASDAQ:VRSK): Q3 Non-GAAP EPS of $1.44 beats by $0.08; GAAP EPS of $1.24 beats by $0.08. Revenue of $759M (+8.0% Y/Y) beats by $1.58M. Press Release
2021-11-03T00:00:00
2021-11-03T00:00:00
205.559998
208.970001
207.970001
203.729996
201.740005
202.369995
200.270004
199.990005
198.809998
201.630005
203.729996
206.740005
207.470001
206.529999
207.75
208.369995
211.550003
210.630005
211.039993
212.050003
211.929993
213.139999
213.960007
212.020004
211.320007
207.880005
209.320007
210.270004
208.940002
209.309998
214.289993
216.600006
214.589996
214.910004
216.289993
213.820007
212.990005
216.270004
218.029999
222.600006
224.5
226.720001
230.029999
228.529999
229.320007
228.210007
2021-11-24
VRSK
Jobless claims are at decades lows; Jefferies picks the best stocks for labor shortages
gguy44/iStock via Getty Images "On virtually every employment indicator, the US labor market is sizzling hot," Jefferies says. This morning, the Labor Department reported that weekly jobless claims fell to 199K from 260K, the lowest number since 1969. While seasonal adjustments mean the numbers will reverse next week, "the trend in claims is clearly falling," Pantheon Macroecomomics says. "Laying off staff is risky when the labor market is so tight, with near-record job openings." Jefferies equity strategist Sean Darby and quant strategist Kenneth Chan recently issued their 2022 outlook, including investment themes uncorrelated to their broader market forecast. In a theme entitled "Workers of the World Unite!" they say that job openings and quits rates at record highs while unemployment is still well off cyclical lows is "particularly pertinent." "Indeed, Jefferies US economics team has highlighted that US strike activity near doubled in October," they write. "One other example of US labor tightness is that the number of job vacancies is outstripping those unemployed." They remain "favorably disposed" to the S&P 500 Professional Services (SP500-202020) group. In that group, Jefferies' top picks are Equifax (NYSE:EFX), Leidos (NYSE:LDOS), Nielsen (NYSE:NLSN) and Verisk Analytics (NASDAQ:VRSK). See how Seeking Alpha's Quant Rating ranks HR and employment services stocks and find more companies with this screen.
2021-11-25T00:00:00
2021-11-26T00:00:00
211.550003
210.630005
211.039993
212.050003
211.929993
213.139999
213.960007
212.020004
211.320007
207.880005
209.320007
210.270004
208.940002
209.309998
214.289993
216.600006
214.589996
214.910004
216.289993
213.820007
212.990005
216.270004
218.029999
222.600006
224.5
226.720001
230.029999
228.529999
229.320007
228.210007
225.809998
229.160004
224.869995
219.639999
225.869995
221.649994
221.910004
225.440002
229.050003
224.5
226.660004
228.940002
224.800003
228.570007
229.199997
222.139999
2021-12-13
VRSK
Verisk Analytics goes ex-dividend tomorrow
Verisk Analytics (NASDAQ:VRSK) had declared $0.29/share quarterly dividend, in line with previous. Payable Dec. 31; for shareholders of record Dec. 15; ex-div Dec. 14. See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth.
2021-12-14T00:00:00
2021-12-14T00:00:00
208.940002
209.309998
214.289993
216.600006
214.589996
214.910004
216.289993
213.820007
212.990005
216.270004
218.029999
222.600006
224.5
226.720001
230.029999
228.529999
229.320007
228.210007
225.809998
229.160004
224.869995
219.639999
225.869995
221.649994
221.910004
225.440002
229.050003
224.5
226.660004
228.940002
224.800003
228.570007
229.199997
222.139999
221.309998
221.990005
223.850006
225.529999
227.410004
228.080002
229.300003
228.089996
228.729996
221.660004
221.729996
214.309998
2018-12-13
VRTX
Vertex Pharma's Orkambi OK'd in Canada for young children
Health Canada approves Vertex Pharmaceuticals' (NASDAQ:VRTX) ORKAMBI (lumacaftor/ivacaftor) for children aged 2-5 years old with cystic fibrosis who harbor two copies of the F508del CFTR mutation. The FDA approved the expanded use in August.
2018-12-14T00:00:00
2018-12-14T00:00:00
169.460007
175.190002
173.289993
174.589996
175.229996
183.880005
180.259995
180.550003
172.850006
170.309998
164.580002
166.669998
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
2018-12-17
VRTX
Vertex Pharmaceuticals CFO bids adieu
Vertex Pharmaceuticals (VRTX -2.2%) announces that Thomas Graney will resign as Chief Financial Officer (CFO) effective immediately. Ian F. Smith, Executive VP and Chief Operating officer, assumed the additional role of interim CFO on December 13.
2018-12-18T00:00:00
2018-12-18T00:00:00
173.289993
174.589996
175.229996
183.880005
180.259995
180.550003
172.850006
170.309998
164.580002
166.669998
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
2018-12-18
VRTX
Vertex Pharma's VX-150 successful in mid-stage neuropathy study
Results from a Phase 2 clinical trial evaluating Vertex Pharmaceuticals' (NASDAQ:VRTX) VX-150 in patients with pain caused by small fiber neuropathy showed a treatment benefit. The study met the primary endpoint of a statistically significant reduction in pain as measured by the change from baseline at week 6 in weekly average pain intensity on a scale called NRS. On the safety front, VX-150 was generally well-tolerated. The most frequent adverse event was headache (24% of patients in the treatment group versus 12% for placebo). The company says the trial is the third successful proof-of-concept study supporting Breakthrough Therapy-tagged VX-150, an inhibitor of a sodium ion channel subtype called NaV1.8 that plays a key role in the transmission of pain signals by nerve cells. A Phase 2 study of VX-150 in patients with pain following bunionectomy (removal of a bunion at the base of the big toe) is underway. Vertex is developing a range of preclinical pain molecules, the first of which should reach the clinic next year.
2018-12-19T00:00:00
2018-12-19T00:00:00
174.589996
175.229996
183.880005
180.259995
180.550003
172.850006
170.309998
164.580002
166.669998
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
2018-12-19
VRTX
Vertex aiming for Orkambi and Symkevi use by NHS in Scotland
With an eye on inclusion in the National Health Service (NHS) formulary in Scotland, Vertex Pharmaceuticals (VRTX +0.1%) plans to submit ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor), to be used with ivacaftor (KALYDECO), to the Scottish Medicines Consortium for assessment. If accepted for NHS use, patients could have access in 2019. The company says there are ~900 people in Scotland with cystic fibrosis.
2018-12-20T00:00:00
2018-12-20T00:00:00
175.229996
183.880005
180.259995
180.550003
172.850006
170.309998
164.580002
166.669998
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
2018-12-27
VRTX
Oppenheimer sees 1H19 risk for smid-cap biotech
Oppenheimer says small- to mid-cap biotech stocks could have more downside risk going into the new year after this quarter's pullback while the historically low valuations for large-cap companies could reach the lowest point. The firm expects underperformance in 1H19 due in part to a negative macro environment. Analyst Hartaj Singh remains bullish on the sector despite the "rough" three- to five-year stretch. Favored companies combine sustained earnings and pipeline catalysts: (REGN -1.9%), (ALXN -0.8%), (VRTX -1.1%). Small-caps with upcoming catalysts: (ATNM -0.5%), (CATB +0.8%), (SLS), (SNSS). Source: Bloomberg First Word.
2018-12-28T00:00:00
2018-12-28T00:00:00
170.309998
164.580002
166.669998
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
2018-12-31
VRTX
Vertex ups stake in CRISPR Therapeutics to 10.4%
CRISPR Therapeutics (CRSP +2.4%) discloses that CTX001 collaboration partner Vertex Pharmaceuticals (VRTX) has increased its stake to 10.4% (~5.4M shares). CRISPR/Cas9 competitors Editas Medicine (EDIT +5.9%) and Intellia Therapeutics (NTLA +2%) are up as well.
2019-01-01T00:00:00
2019-01-02T00:00:00
166.669998
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
2018-12-31
VRTX
Proteostasis up 8% after hours on successful Phase 1 study of PTI-428
Proteostasis Therapeutics (NASDAQ:PTI) is up 8% after hours on the heels of its Phase 1 clinical trial evaluating PTI-428 in cystic fibrosis patients on background Kalydeco (ivacaftor) therapy. The company says the study met the primary (safety and tolerability) and secondary endpoints (pharmacokinetics) but it did not perform exploratory analyses on other measures (efficacy) due to the small number of enrollees. Related ticker: (NASDAQ:VRTX)
2019-01-01T00:00:00
2019-01-02T00:00:00
166.669998
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
2019-01-02
VRTX
Drug makers OK with price inclusion in TV ads if done fairly
Four members of Big Pharma, Pfizer (PFE -1.6%), Sanofi (SNY -1.6%), Eli Lilly (LLY -1.5%) and Johnson & Johnson (JNJ -0.9%), responding to the federal government's proposed inclusion of prices in TV drug ads generally support the value of increased transparency for patients, but caution that it needs to be done fairly. They say that including just the list price will confuse patients since most are only responsible for co-payments. Some may not fill prescriptions if they perceive that they will have to pay the full monty (shockingly high in many cases). J&J says that if list price disclosures are required for drugs, then hospitals, health insurers and pharmacy benefit managers should play by similar rules. Sanofi was the least supportive, regarding CMS's proposal as "oversimplified" since would fail to grasp the "nuance and complexity" of prescription drugs and biologics. The trade association, Pharmaceutical Research and Manufacturers of America (PhRMA), has proposed its own voluntary guidelines that will take effect in April. It prefers to link drug price information to ads and wants to partner with advocacy groups on an online patient affordability platform that will allow them to access information on insurance coverage, co-payments and other factors in addition to drug prices. The 60-day comment period ended last month. CMS will now decide on the specific regulation. Legal challenges are a near certainty if prices are required in advertisements. Selected tickers: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA, XLV, XBI, VHT, IYH, RYH, IBB, XHE, PJP, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, ESRX, WBA, CVS, UNH, CELG, LLY, CI
2019-01-03T00:00:00
2019-01-03T00:00:00
165.110001
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
2019-01-03
VRTX
Vertex teams up with Arbor Biotech in gene-editing therapies
Vertex Pharmaceuticals (NASDAQ:VRTX) will collaborate with Arbor Biotechnologies to discover novel proteins for gene-editing therapies for cystic fibrosis and four other yet-to-be-named diseases. The partnership will leverage Arbor's protein biodiscovery platform based on machine learning, genome sequencing, gene synthesis and high-throughput screening. The specific focus will be on programmable DNA endonucleases with high fidelity and catalytic activity. VRTX will pay Arbor an upfront amount, research funding, milestones and royalties on net sales. Specific financial terms are not disclosed.
2019-01-04T00:00:00
2019-01-04T00:00:00
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
2019-01-03
VRTX
BMY/Celgene tie-up buoys Gilead and Vertex premarket
Gilead Sciences (NASDAQ:GILD) is up 3% and Alexion Pharmaceuticals (NASDAQ:VRTX) is up 1% premarket, albeit both on modest volume, on the heels of Bristol-Myers Squibb's $74B bid for fellow biotech Celgene.
2019-01-04T00:00:00
2019-01-04T00:00:00
161.070007
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
2019-01-04
VRTX
Biotechs lead broad market advance, XBI up 5%
Biotech and healthcare companies are enjoying robust buying in conjunction with the broad market. The SPDR S&P Biotech ETF (XBI +5.1%) is ahead of the major indexes, albeit on below-average volume. Selected tickers: (XLV +3.5%)(BIB +10.7%)(PJP +3.7%)(VHT +3.8%)(IYH +3.7%)(IBB +5.4%)(OTCQX:RHHBY +1.1%)(ABBV +3.1%)(AGN +4.7%)(AZN +2.6%)(BMY +4.9%)(MRK +3.2%)(NVS +1.8%)(BHC +5.1%)(TEVA +6.1%)(BIIB +5.2%)(AMGN +3.7%)(GILD +4.3%)(CELG +6.2%)(VRTX +5.3%)(XTLB +10.4%)(VTL +18.4%)(SNDX +16.9%)(SPHS +24.3%)(SCYX +15.2%)(RETA +12.8%)(PBYI +3.2%)(HSGX +23.9%)(FLKS +47.1%)(DRRX +26.1%)(CDTX +10.4%)(CTIC +28.8%)(BPTH +19.6%)(AKAO +44.9%)(FLGT +19%)(CRSP +10.1%)(KRYS +12.1%)
2019-01-05T00:00:00
2019-01-07T00:00:00
159.759995
160.25
160.389999
167.399994
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
2019-01-10
VRTX
Drug applications take back seat to safety surveillance at FDA during shutdown
In a tweet, FDA Commissioner Scott Gottlieb, M.D. says the agency is having to shift resources from premarket drug review work to safety surveillance during the federal government shutdown as President Trump and congressional leaders squabble over the border wall. Drug firms will, no doubt, notify their lobbyists on this development. Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY
2019-01-11T00:00:00
2019-01-11T00:00:00
175.449997
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
2019-01-11
VRTX
Dem lawmakers introduce bill to lower U.S. drug prices
On the heels of a new round of price increases by drug firms and worn-out patience waiting for President Trump to follow through his campaign promise, Senator Bernie Sanders (D-VT) and Representative Elijah Cummings (D-MD 7th District) have introduced a bill aimed at reining in drug prices. Their bill, similar to the Trump administration's idea to benchmark U.S. drug prices to Europe's, would create an "international pricing index" as a means to more closely align the U.S. with other countries. It would also allow the Secretary of Health and Human Services (HHS) to negotiate prices under Medicare Part D and allow Americans to purchase medicines from Canada and other countries. Predictably, the Pharmaceutical Research and Manufacturers of America, the industry's top lobbying organization, is opposed, saying the bill would "interfere with patient access to medicine while also undermining the U.S. intellectual property system, replicating the flawed policies of foreign governments and circumventing the FDA's robust safety standards." Drugmakers blame pharmacy benefit managers (PBMs) for the problem saying they continue to demand ever-increasing rents for inclusion on formularies. Several drugmakers maintained prices for a short while last year, but reinstituted increases this month on more than 250 medications, including top seller Humira at AbbVie. On the plus side, the increases were more modest, with almost all being less than 10%. Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, ABC, CAH, MCK, UNH, CVS, ESRX
2019-01-12T00:00:00
2019-01-14T00:00:00
178.380005
179.449997
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
2019-01-15
VRTX
FDA Commish touts advances/successes
In a stream of tweets, FDA Commissioner Scott Gottlieb, M.D. details a number of accomplishments and advances by the agency. Highlights: Federal government shutdown: About 400 (or 410) staffers are returning to work to conduct key inspections: ~150 in food, ~100 in high-risk medical device manufacturing, ~70 in high-risk drug manufacturing and ~90 in high-risk biologic manufacturing. They plan to work without pay this week. Generics and biosimilar programs will be negatively impacted if the shutdown persists. Carryover fees are funding the work at present. Higher-risk products are being prioritized. Seven biosimilars were approved in 2018, raising the cumulative total to 16. 70 programs are in process. Five generic drugs were approved last year under the new competitive generic therapy designation (accelerated revenue and 180 days of market exclusivity). "First generics" comprised almost 10% of the 971 generic drug applications approved in fiscal 2018 (no prior generic was on the market). The total number of approvals was a record for the agency. 1,021 were approved in calendar 2018. Selected tickers: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA, XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, PRGO, MYL, MNK, RDY, AKRX
2019-01-16T00:00:00
2019-01-16T00:00:00
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
2019-01-16
VRTX
Hospitals squeezed by high drug costs
A study funded by the American Hospital Association, Federation of American Hospitals and the American Society of Health-System Pharmacists found that total drug spend per hospital admission rose 18.5% between 2015 and 2017, adding $1.8M in additional costs for an average hospital. Outpatient drug spending per admission rose almost 30% while inpatient spending for medicines rose 10%. Price hikes as high as 80% or more occurred in anesthetics, parenteral solutions, opioid agonists and chemo. More than 90% of hospitals surveyed had to identify alternative therapies to mitigate the impact of price increases and drug shortages. One in four had to downsize staff. The price of Roche's stroke med Activase increased 19% to $4,143. Johnson & Johnson's Remicade, AbbVie's Humira and Amgen's Enbrel increased between 15 - 21%. The majority of hospitals reported that competition had little effect on prices. Two of the 10 most expensive drugs in fiscal 2017 had generic or biosimilar alternatives enter the market in 2016, but the two still increased 4.1%, albeit more modestly than the 14.4% average hike among the other eight. About 750 hospitals have joined a non-profit venture called Civica Rx aimed at managing drug costs and supply. XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY Â
2019-01-17T00:00:00
2019-01-17T00:00:00
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
2019-01-15
VRTX
FDA to beef up cell and gene therapy staff
Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 such therapies per year by 2025. 50 new clinical reviewers will be added (certainly contingent on the resolution of the federal government impasse between President Trump and Congress). New policy guidance will be issued this year. The agenda includes working with sponsors to make maximum use of accelerated programs, including regenerative medicine advanced therapy (RMAT) designation, a series of clinical guidance documents to inform product development, including gene therapies for blood disorders, and how to use the accelerated approval pathway in cases where the gene therapy addresses the underlying genetic defect. The guidance will also include information designed to help in the development of CAR-T therapies (and other cellular products) and to promote a better understanding of the critical factors in manufacturing with the goal of allowing minor manufacturing changes without requiring new bridging studies. Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, XON, ALNY, CLLS, SRNE, ZIOP, CYAD, BLUE, NTLA, CRSP, EDIT, SRPT, SLDB, RCKT, RGNX, BGNE, SGMO, ONCE, VYGR
2019-01-16T00:00:00
2019-01-16T00:00:00
180.789993
184.649994
177.929993
179.610001
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
2019-01-22
VRTX
Expanded use of Vertex Pharma's Orkambi OK'd in Europe
The European Commission has approved the use of Vertex Pharmaceuticals' (NASDAQ:VRTX) ORKAMBI (lumacaftor/ivacaftor) for children ages 2 - 5 years old with cystic fibrosis who have two copies of the F508del mutation. It was previously approved for children at least six years old who have two copies of the mutation.
2019-01-23T00:00:00
2019-01-23T00:00:00
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
2019-01-22
VRTX
Editas and CRISPR weigh on biotechs, XBI down 3%
The broad market's down day notwithstanding, biotechs are getting drubbed, led by Editas Medicine and CRISPR Therapeutics. The SPDR S&P Biotech ETF (XBI -2.9%) is down, albeit on average volume. Selected tickers: (IONS -1.5%)(FPRX -2.3%)(GBT -2.4%)(INCY -1.5%)(UTHR -2.1%)(PBYI -2.9%)(NKTR -3.6%)(EXAS -3.4%)(BPMC -2.8%)(BMRN -2%)(CLVS -2.6%)(CELG -1.5%)(GLPG -0.8%)(BGNE -3.6%)(ALKS -3.2%)(ALNY -3.8%)(VRTX -0.6%)(GILD -0.8%)(BIIB -0.2%)(AMGN -0.8%)
2019-01-23T00:00:00
2019-01-23T00:00:00
172.210007
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
2019-01-24
VRTX
Vertex announces departure of Ian Smith, Names interim CFO
Vertex (NASDAQ:VRTX -0.7%) says that Ian Smith has been terminated as COO and Interim CFO, effective immediately. Paul Silva, Senior Vice President and the Company’s Corporate Controller and Chief Accounting Officer since 2008, has been appointed interim CFO. Press Release
2019-01-25T00:00:00
2019-01-25T00:00:00
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
2019-01-23
VRTX
Vertex boots COO over "personal behavior"
Vertex Pharmaceuticals (NASDAQ:VRTX) has fired COO and CFO Ian Smith over "personal behavior that violated Vertex's Code of Conduct." Corporate Controller and Chief Accounting Officer Paul Silva will take over the CFO job on an interim basis until a permanent successor is appointed. Shares are down 1% after hours.
2019-01-24T00:00:00
2019-01-24T00:00:00
173.779999
173.229996
175.449997
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
2019-01-28
VRTX
Expanded use for Vertex's Kalydeco OK'd in Canada
Health Canada approves the use of Vertex Pharmaceuticals' (NASDAQ:VRTX -0.7%) KALYDECO (ivacaftor) to include children with cystic fibrosis ages 12 to <24 months who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. The FDA approved the expanded label in August 2018, followed by EMA approval in Europe three months later.
2019-01-29T00:00:00
2019-01-29T00:00:00
173.419998
170.059998
166.169998
163.429993
158.660004
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
2019-02-04
VRTX
Vertex Pharmaceuticals Q4 2018 Earnings Preview
Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q4 earnings results on Tuesday, February 5th, after market close. The consensus EPS Estimate is $1.06 (+73.8% Y/Y) and the consensus Revenue Estimate is $820.13M (+25.9% Y/Y). Over the last 2 years, VRTX has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time. Over the last 75 days, EPS estimates have seen 5 upward revisions and 3 downward. Revenue estimates have seen 4 upward revisions and 1 downward.
2019-02-05T00:00:00
2019-02-05T00:00:00
161.300003
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
2019-02-06
VRTX
B. Riley sees 144% upside for Genfit in premarket analyst action
Genfit SA (OTCPK:GNFTF) initiated with Buy rating and a €46 (144% upside) price target at B. Riley FBR citing an expected positive outcome from the Phase 3 RESOLVE-IT study evaluating elafibranor in NASH. CymaBay Therapeutics (NASDAQ:CBAY) initiated with Neutral rating with a $9 (flat) price target at B. Riley FBR citing valuation. Vertex Pharmaceuticals (NASDAQ:VRTX) downgraded to Hold at Maxim Group citing valuation. Shares up 4% premarket after Q4 results released after the close yesterday.
2019-02-07T00:00:00
2019-02-07T00:00:00
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
2019-02-05
VRTX
Vertex Q4 non-GAAP earnings up 113%; shares up 2% after hours
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 results ($M): Revenues: 870.1 (+33.5%); product revenues: 868.2 (+39.8%). Key product sales: Kalydeco: 259 (+1.2%); Orkambi: 315 (-13.7%); Symdeko: 294. Net income: 1,550.5 (+999%) - increase due to $1.5B income tax benefit. Non-GAAP net income: 336.9 (+113.4%). EPS: $5.97 (+999%); non-GAAP EPS: 1.30 (+113.1%). 2019 guidance: CF product revenues: $3.45B - 3.55B. Previously: Vertex Pharmaceuticals beats by $0.24, beats on revenue (Feb. 5)
2019-02-06T00:00:00
2019-02-06T00:00:00
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
2019-02-05
VRTX
Vertex Pharmaceuticals beats by $0.24, beats on revenue
Vertex Pharmaceuticals (NASDAQ:VRTX): Q4 Non-GAAP EPS of $1.30 beats by $0.24; GAAP EPS of $5.97 beats by $5.29. Revenue of $869.4M (+39.6% Y/Y) beats by $49.27M. Press Release
2019-02-06T00:00:00
2019-02-06T00:00:00
156.5
151.910004
161.839996
162.369995
161.419998
165.710007
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
2019-02-14
VRTX
Vertex's tezacaftor/ivacaftor successful in late-stage CF study in young kids
A Phase 3 clinical trial conducted in Europe and Australia evaluating the combination of Vertex Pharmaceuticals' (NASDAQ:VRTX -0.2%) tezacaftor and ivacaftor in children aged 6 - 11 years with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one residual function mutation met the primary endpoint. The data showed that treatment with the combination produced a statistically significant improvement in lung function, measured by the absolute change in lung clearance index, compared to placebo. The combination, branded as Symdeko (tezacaftor/ivacaftor and ivacaftor), is currently approved in the U.S. and Europe for CF patients at least 12 years old. The company submitted its U.S. marketing application for the expanded patient population last quarter. It expects to file its application in Europe in H2.
2019-02-15T00:00:00
2019-02-15T00:00:00
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
2019-02-13
VRTX
Vertex files for mixed shelf offering
Vertex Pharmaceuticals (NASDAQ:VRTX) has filed a prospectus for an unspecified mixed shelf offering.
2019-02-14T00:00:00
2019-02-14T00:00:00
164.080002
163.729996
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
2019-02-15
VRTX
FDA creates new accelerated review pathway for generic drug applications
In a statement, FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient populations and/or are difficult to copy due to their complexity. The designation, called Competitive Generic Therapies (CGT), provides for more intensive FDA guidance on development as well as a shorter review clock. An approved abbreviated new drug application (ANDA) for a CGT-tagged generic medicine will also enjoy a 180-day period of market exclusivity (no real change here since this is the same exclusivity period for an approved "first-to-file" application). Dr. Gottlieb says the agency has signed off on 100 CGT requests to date with five ANDAs approved in 2018 (August - December). Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, PFE, CELG, LLY, GNRX, PRGO, MYL, LCI, AKRX, MNK, RDY
2019-02-16T00:00:00
2019-02-19T00:00:00
172.699997
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
2019-02-19
VRTX
Maryland strikes out in reviving drug price-gouging law
The U.S. Supreme Court has rejected the state of Maryland's appeal of an appeals court ruling that struck down its anti-price gouging law citing the illegality of state-level regulation of interstate commerce. A trade group representing generic drugmakers filed the legal challenge to the law. Maryland's law, enacted in 2017 after high-profile price hikes by certain pharma firms, including Turing Pharmaceuticals with Daraprim, prohibited "unconscionable" price increases for essential off-patent medicines or generics sold there. XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, PRGO, MYL, RDY, AKRX
2019-02-20T00:00:00
2019-02-20T00:00:00
175.850006
178.190002
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
2019-02-21
VRTX
Biotechs under pressure, XBI down 1.4%
Biotechs can't find any love this morning. The SPDR S&P Biotech ETF (XBI -1.4%) is down, albeit on below-average volume. Recent action is a bit negative, including modest pressure on Celgene (CELG -1.3%) related to merger rumors, Biogen (BIIB -3.7%) after a Stifel downgrade and some soft earnings and/or guidance. Selected tickers: (IONS -1.5%)(GBT -0.7%)(INCY -1.5%)(CRSP -3.4%)(EDIT -3.5%)(NTLA -7.4%)(XON -0.9%)(UTHR -0.1%)(SAGE -0.8%)(REGN -0.8%)(PBYI -0.9%)(NKTR -4.7%)(EXAS -1.6%)(BPMC -4%)(CLVS -0.9%)(GLPG -1.9%)(BLUE -3.1%)(BGNE -1.1%)(ALKS -1.8%)(ALXN -2.3%)(VRTX -1.6%)(GILD -1.6%)(AMGN -0.8%)
2019-02-22T00:00:00
2019-02-22T00:00:00
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
2019-02-21
VRTX
U.S. healthcare spending to rise 5.5% per annum over next decade
According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is expected to rise 5.5% each year over the next decade, reaching ~$6T by 2027 (19.4% of GDP). Medicare spending is expected to rise 7.4% per annum over the same period, above 5.5% for Medicaid and 4.8% for private insurance plans. Medicare enrollment should peak at 2.9% this year. Prescription drug spending is forecasted to rise 5.6% per year between 2018 and 2027 as is hospital spending. By 2027, federal, state and local governments are projected to fund 47% of national healthcare spending (45% in 2017). Selected tickers: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA, XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, CI, CNC, HUM, HCA, ANTM, UNH, CVS, WCG, MOH
2019-02-22T00:00:00
2019-02-22T00:00:00
182.300003
186.029999
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
2019-02-25
VRTX
First patient dosed in study of gene therapy CTX001 in beta thalassemia
CRISPR Therapeutics (NASDAQ:CRSP) and development partner Vertex Pharmaceuticals (NASDAQ:VRTX) announce that the first beta thalassemia patient has been dosed with CTX001, a gene therapy based on the CRISPR/Cas9 gene editing approach. The patient is enrolled in a Phase 1/2 study evaluating CTX001 in patients with hemoglobin disorders. The first sickle cell disease subject should be dosed by mid-year. CRSP is up 11% premarket, stoked by Roche's bid for Spark Therapeutics.
2019-02-26T00:00:00
2019-02-26T00:00:00
188.160004
183.910004
186.679993
186.149994
190.520004
194.699997
193.880005
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
2019-03-06
VRTX
Biotechs remain under pressure on Gottlieb exit
Investors are avoiding biotechs in the wake of the abrupt resignation notice from FDA Commissioner Scott Gottlieb, M.D. who was a champion of more efficient and responsive agency action, although punters should expect another industry-friendly chief from the Trump administration. Selected tickers: SPDR S&P Biotech ETF (XBI -2.9%), Biogen (BIIB -1.8%), Amgen (AMGN -3%), Intrexon (XON -2.4%), Ionis Pharmaceuticals (IONS -2.4%), Nektar Therapeutics (NKTR -4.2%), Gilead Sciences (GILD -2%), Clovis Oncology (CLVS -4.3%), Vertex Pharmaceuticals (VRTX -2.6%), bluebird bio (BLUE -2.7%), BioMarin Pharmaceutical (BMRN -1.2%)
2019-03-07T00:00:00
2019-03-07T00:00:00
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
2019-03-06
VRTX
Vertex's VX-445 triple combo successful in two late-stage CF studies
Vertex Pharmaceuticals (NASDAQ:VRTX) announces positive outcomes from two Phase 3 clinical trials evaluating the combination of next-generation corrector VX-445, tezacaftor and ivacaftor in cystic fibrosis (CF) patients. In the trial with CF patients with one F508del mutation and one minimal function mutation, treatment with the triple combo produced a mean absolute improvement in lung function of 13.8% (measured by ppFEV1) at week 4 compared to placebo (p<0.0001). In the trial with CF patients with two F508del mutations, ppFEV1 improved 10.0% at week 4 compared to control (p<0.0001). The company says the results are similar to the triple combination of VX-659, tezacaftor and ivacaftor that were reported in Q4 2018 with a similar safety profile. It will assess 24-week data, expected next quarter, before selecting the best regimen for global marketing applications. It expects to file its application in the U.S. in Q3 followed by Europe in Q4. CF is caused by mutations in the CFTR gene which prevents the CFTR protein from being made correctly, leading to an imbalance of salt and fluids inside and outside of cells. A corrector molecule helps the CFTR protein form the right shape so that it is able to move to the cell surface allowing chloride to pass out of the cell, reducing CF symptoms.
2019-03-07T00:00:00
2019-03-07T00:00:00
189.889999
186.580002
189.5
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
2019-03-12
VRTX
Biotechs (mostly) in the green on Sharpless nod to head FDA
Biotech investors appear to be comfortable with FDA Commissioner designee Norman Sharpless who has run the NCI since 2017. Selected tickers: Ionis Pharmaceuticals (IONS +0.7%), Incyte (INCY +0.8%), Intrexon (XON +3.4%), CRISPR Therapeutics (CRSP +1.4%), Editas Medicine (EDIT +2.6%), Intellia Therapeutics (NTLA +1.3%), bluebird bio (BLUE -0.5%), BioMarin Pharmaceutical (BMRN +1.4%), Vertex Pharmaceuticals (VRTX +1.1%), Amgen (AMGN), Gilead Sciences (GILD +0.7%), Biogen (BIIB +0.7%), Galapagos N.V. (GLPG -0.5%), Alexion Pharmaceuticals (ALXN +1.6%), Alnylam Pharmaceuticals (ALNY +0.1%)
2019-03-13T00:00:00
2019-03-13T00:00:00
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
2019-03-12
VRTX
Vertex's Symdeko OK'd in Australia
The Australian Therapeutic Goods Administration approves Vertex Pharmaceuticals' (NASDAQ:VRTX) SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for the treatment of patients with cystic fibrosis (CF) at least 12 years old who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor. Reimbursement will be considered at this month's meeting of the Pharmaceutical Benefits Advisory Committee.
2019-03-13T00:00:00
2019-03-13T00:00:00
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
2019-03-11
VRTX
Sickle cell players in the green after 60 Minutes piece
Biotechs developing gene therapies for sickle cell disease are seeing a modest uptick in buying after a 60 Minutes segment last night on the preliminary success of an unnamed gene therapy. The patient who was the primary focus appeared to have completely responded and she has been pain-free from vaso-occlusive crises since receiving the one-time treatment. Selected tickers: bluebird bio (BLUE +4.8%), CRISPR Therapeutics (CRSP +3%), Vertex Pharmaceuticals (VRTX +1.4%), Editas Medicine (EDIT +3.8%)
2019-03-12T00:00:00
2019-03-12T00:00:00
188.089996
186.380005
187.050003
190.910004
191.520004
187.979996
187.020004
182.389999
180.179993
181.339996
181.529999
184.009995
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
2019-03-27
VRTX
Eloxx Pharma up 2% on encouraging ELX-02 data
Thinly traded micro cap Eloxx Pharmaceuticals (NASDAQ:ELOX +1.7%) is up on below-average volume on the heels of encouraging preclinical data on lead candidate ELX-02 in cystic fibrosis (CF). The results were presented at the ECFS Basic Science Conference in Croatia. The company says small molecule ELX-02 significantly increased CFTR protein expression in organoids derived from CF patients (CF is caused by mutations in the CFTR gene which causes the deficiency/absence of the CFTR protein). Eloxx plans to launch a Phase 2 study in the U.S. and Europe this year in CF patients carrying at least one G542X mutation, adding that it expects to report topline results this year as well. ELX-02 is a eukaryotic ribosomal selective glycoside, a compound that modulates the ribosome, a part of the cell that plays a major role in protein production. It is designed to increase the read-through activity in patients with nonsense mutations, enabling the production of enough full-length protein to restore biochemical activity. CF-related tickers: Proteostasis Therapeutics (PTI -7.9%); Vertex Pharmaceuticals (NASDAQ:VRTX -0.6%)
2019-03-28T00:00:00
2019-03-28T00:00:00
185.25
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
2019-03-28
VRTX
British CF patients still waiting for routine access to Vertex's Orkambi
Despite European Commission approval in November 2015, cystic fibrosis (CF) patients in Britain still do not have routine access to Vertex Pharmaceuticals' (VRTX -1.6%) ORKAMBI (lumacaftor/ivacaftor) due to an impasse over the price with the Institute for Health and Care Excellence (NICE), the cost and care quality advisor to the National Health Service (NHS). The company recently destroyed almost 8,000 packs of expired product that was earmarked for the EU, including the UK. Last year, British health officials offered £500M over five years and £1B over 10 years for NHS access to all of the company's CF drugs but the company stiff-armed the proposal as inadequate citing the substantial cost to develop the meds. CEO Jeff Leiden, M.D., Ph.D. and CCO Stuart Arbuckle recently appeared before a Parliamentary committee to answer questions on the issue. Dr. Leiden subsequently met with Health Secretary Matt Hancock who told the House of Commons that "constructive" discussions are continuing. About 600 British CF patients have received ORKAMBI through a special access program.
2019-03-29T00:00:00
2019-03-29T00:00:00
185.720001
188.070007
186.860001
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
2019-04-02
VRTX
New finance chief at Vertex
Vertex Pharmaceuticals (NASDAQ:VRTX) appoints Charles Wagner as EVP and CFO effective April 10. He joins the firm from Ortho Clinical Diagnostics where he was CFO and EVP, Finance.
2019-04-03T00:00:00
2019-04-03T00:00:00
187.839996
183.059998
185.759995
186.330002
188.919998
189.809998
188.75
192.160004
190.039993
187.800003
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
2019-04-16
VRTX
CRISPR and Vertex's CTX001 Fast Track'd for beta thalassemia
The FDA designates CRISPR Therapeutics (NASDAQ:CRSP) and development partner Vertex Pharmaceuticals' (NASDAQ:VRTX) gene therapy candidate CTX001 for Fast Track review for the treatment of transfusion-dependent beta thalassemia. A Phase 1/2 open-label study launched in February. CTX001 is also Fast Track-tagged for sickle cell disease. The first patient should be infused mid-year. Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application. CRSP is up 4% premarket on light volume.
2019-04-17T00:00:00
2019-04-17T00:00:00
181.110001
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
2019-04-17
VRTX
Drugmaker selloff intensifies on D.C. pricing headwinds
Investors in biotechs and biopharma firms appear to have intensified their profit-taking after the Q1 run-up, stoked, no doubt, from the sour mood in Congress over high drug prices and the Trump administration's stated priority to tackle the problem. The SPDR S&P Biotech ETF (XBI -4.6%) is down on almost 75% higher volume while the SPDR S&P Pharmaceuticals ETF (XPH -3.2%) is down on almost 33% higher volume (albeit on turnover of only 72K shares). Johnson & Johnson (JNJ +1.4%) is the only one above water. Selected tickers: Biogen (BIIB -1%); Amgen (AMGN -2.2%); AbbVie (ABBV -2.7%); Allergan (AGN -4.1%); Bristol-Myers Squibb (BMY -0.7%); Merck (MRK -3%); Eli Lilly (LLY -2.5%); Pfizer (PFE -2.4%); Teva Pharmaceutical Industries (TEVA -3.2%); GlaxoSmithKline (GSK -0.4%); Novartis (NVS -2.2%); AstraZeneca (AZN -0.7%); Bausch Health (BHC -3.4%); Vertex Pharmaceuticals (VRTX -5.3%); Gilead Sciences (GILD -1.7%); Seattle Genetics (SGEN -5%); CRISPR Therapeutics (CRSP -8.1%); Editas Medicine (EDIT -5.6%); Intellia Therapeutics (NTLA -7.9%); Regeneron Pharmaceuticals (REGN -5%); Incyte (INCY -3.1%); Intrexon (XON -10.7%); Alexion Pharmaceuticals (ALXN -7.1%); BioMarin Pharmaceutical (BMRN -6%)
2019-04-18T00:00:00
2019-04-18T00:00:00
178.610001
177.259995
180.520004
182.570007
185.660004
186.110001
188.089996
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
2019-04-30
VRTX
FDA OKs expanded use of Vertex's Kalydeco
Vertex Pharmaceuticals (NASDAQ:VRTX) announces that the FDA has approved KALYDECO (ivacaftor) for the treatment of children as young as six months old with cystic fibrosis who have at least one mutation in the CFTR gene. Previously, the product was approved for use in kids as young as 12 months old. Shares are up a fraction premarket.
2019-05-01T00:00:00
2019-05-01T00:00:00
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
2019-04-29
VRTX
Vertex Pharmaceuticals Q1 2019 Earnings Preview
Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q1 earnings results on Tuesday, April 30th, after market close. The consensus EPS Estimate is $1.01 (+32.9% Y/Y) and the consensus Revenue Estimate is $853M (+33.1% Y/Y). Over the last 2 years, vrtx has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time. Over the last 3 months, EPS estimates have seen 6 upward revisions and 7 downward. Revenue estimates have seen 5 upward revisions and 3 downward.
2019-04-30T00:00:00
2019-04-30T00:00:00
187.479996
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
2019-04-30
VRTX
Vertex posts healthy Q1; revenues up 34%; earnings up 28%
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 results ($M): Revenues: 858.4 (+34.0%); product sales: 857.3 (+34.4%). Key product sales: Symdeco/Symkevi: 320 (+841.2%); Orkambi: 293 (-17.2%); Kalydeco: 244 (-2.4%). Net income: 269 (+28.1%); non-GAAP net income: 296 (+51.0%); EPS: 1.03 (+27.2%); non-GAAP EPS: 1.14 (+50.0%). 2019 guidance: Product sales: $3.45B - 3.55B (unch). Previously: Vertex Pharmaceuticals beats by $0.13, beats on revenue (April 30)
2019-05-01T00:00:00
2019-05-01T00:00:00
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
2019-04-30
VRTX
Vertex Pharmaceuticals beats by $0.13, beats on revenue
Vertex Pharmaceuticals (NASDAQ:VRTX): Q1 Non-GAAP EPS of $1.14 beats by $0.13; GAAP EPS of $1.03. Revenue of $858.44M (+34.0% Y/Y) beats by $5.44M. Press Release
2019-05-01T00:00:00
2019-05-01T00:00:00
181.759995
179.979996
182.559998
181.529999
183.850006
189.910004
185.820007
182.419998
183.949997
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
2019-05-13
VRTX
FDA finalizes guidance on interchangeable biosimilars
The FDA has completed its long-anticipated guidance on interchangeability of biosimilars, allowing their substitution for reference biologics without prescribers' sign-off. None has been approved in the U.S. yet, but Boehringer Ingelheim is working on interchangeability status for its biosimilar to AbbVie's (NYSE:ABBV) Humira (adalimumab). Interchangeable insulin products should coming in the next few years. A key requirement of the new guidelines is a "switching study" aimed at demonstrating that alternating between the biosimilar and branded product does not impact safety or efficacy. ETFs: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA Selected tickers: Biogen (NASDAQ:BIIB); Amgen (NASDAQ:AMGN); Vertex Pharmaceuticals (NASDAQ:VRTX); Gilead Sciences (NASDAQ:GILD); Takeda (NYSE:TAK); Bausch Health (NYSE:BHC); Roche (OTCQX:RHHBY); Allergan (NYSE:AGN); AstraZeneca (NYSE:AZN); Bristol-Myers Squibb (NYSE:BMY); GlaxoSmithKline (NYSE:GSK); Johnson & Johnson (NYSE:JNJ); Eli Lilly (NYSE:LLY); Merck (NYSE:MRK); Novo Nordisk (NYSE:NVO); Novartis (NYSE:NVS); Pfizer (NYSE:PFE); Teva Pharmaceutical Industries (NYSE:TEVA)
2019-05-14T00:00:00
2019-05-14T00:00:00
186.050003
187.110001
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
173.009995
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
2019-05-15
VRTX
Vertex teams up with Kymera to advance small molecule protein degraders
Vertex Pharmaceuticals (NASDAQ:VRTX) inks a four-year R&D collaboration agreement with privately held Kymera Therapeutics aimed at advancing therapies called protein degraders against a range of targets. The partnership will leverage Kymera's Pegasus drug discovery platform with Vertex's scientific, clinical and regulatory know-how to accelerate the development of a line-up of drugs for serious diseases. Kymera says targeted protein degraders are bifunctional small molecules that can theoretically target "undruggable" and "difficult-to-drug" proteins via harnessing the body's natural cellular processes to eliminate disease-causing proteins. Under the terms of the deal, VRTX will pay Kymera $70M upfront, up to $1B in potential milestones for up to six programs and tiered royalties on net sales.
2019-05-16T00:00:00
2019-05-16T00:00:00
187.889999
184.149994
188.889999
188.929993
188.309998
190.369995
185.119995
182.779999
182.490005
179.740005
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
173.009995
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
167.75
173.509995
2019-05-30
VRTX
Vertex selects triple CF combo for global regulatory filings
Vertex Pharmaceuticals (NASDAQ:VRTX) has selected the combination of elexacaftor (VX0445), tezacaftor and ivacaftor as its new cystic fibrosis (CF) therapy for patients at least 12 years old with one F508del mutation and one minimal function mutation and in those with two F508del mutations. Elexacaftor is a next-generation corrector while tezacaftor and ivacaftor are the active ingredients in SYMDEKO. It plans to file its U.S. marketing application next quarter followed by an application in Europe in Q4.
2019-05-31T00:00:00
2019-05-31T00:00:00
166.970001
168.160004
168.520004
175.369995
172.580002
174.610001
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
173.009995
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
167.75
173.509995
172.839996
172
170.630005
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
2019-06-07
VRTX
Elox Pharma up 34% on positive data on lead CF candidate
Thinly traded micro cap Eloxx Pharmaceuticals (NASDAQ:ELOX +33.9%) is up on a 6x surge in volume, albeit on only 179K shares, in reaction to new data on lead candidate ELX-02, in Phase 2 development for cystic fibrosis (CF) and cystinosis. The results were presented at the European Cystic Fibrosis Society Conference in Liverpool. Studies showed that ELX-02 increased/restored functional CFTR protein in a dose-dependent manner and increased CFTR messenger RNA (mRNA) to healthy control levels. It also demonstrated a favorable safety profile with high (98%) bioavailability via subcutaneous injection. ELX-02 is a eukaryotic ribosomal selective glycoside, a compound that modulates the ribosome, a part of the cell that plays a major role in protein production. It is designed to increase the read-through activity in patients with nonsense mutations, enabling the production of enough full-length protein to restore biochemical activity. CF is caused by the absence or dysfunction of a protein called CFTR that controls the movement of salt and water in an out of cells. The cause of the absence or dysfunction of the protein is genetic mutations in the gene that encodes CFTR. CF-related tickers: Vertex Pharmaceuticals (NASDAQ:VRTX -2.7%), Proteostasis Therapeutics (PTI -4.5%), Corbus Pharmaceuticals (NASDAQ:CRBP +1.5%)
2019-06-08T00:00:00
2019-06-10T00:00:00
172.850006
172.520004
168.979996
172.600006
169.539993
173.869995
174.759995
170.279999
169.009995
169.910004
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
173.009995
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
167.75
173.509995
172.839996
172
170.630005
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
2019-06-21
VRTX
FDA approves expanded indication of Symdeko for cystic fibrosis
Vertex Pharmaceuticals (NASDAQ:VRTX +0.9%) says it received Food and Drug Administration approval of its Symdeko (tezacaftor/ivacaftor and ivacaftor) tablets for treatment of pediatric patients with cystic fibrosis aged 6-11 who have certain genetic mutations. VRTX says a Phase 3 study of Symdeko in children 6-11 showed the regimen was generally well tolerated with safety data similar to previous studies of patients aged 12 years and older. Symdeko already was approved by the FDA for the treatment of cystic fibrosis in patients 12 years and older with certain mutations, and an additional dosage strength of the tablet is now available in connection with this approval.
2019-06-22T00:00:00
2019-06-24T00:00:00
168.850006
164.610001
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
173.009995
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
167.75
173.509995
172.839996
172
170.630005
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
2019-06-25
VRTX
Pharma players in green on AbbVie/Allergan deal
Members of Big Biopharma, with the notable exception of AbbVie, are all enjoying a spike in buying after its $63B bid for Allergan, stoking hopes that big healthcare mergers are back in play. Selected tickers: Takeda (TAK +1.3%), Bausch Health Companies (BHC +4.2%), Roche (OTCQX:RHHBY +0.2%), AstraZeneca (AZN +0.2%), Bristol-Myers Squibb (BMY +1%), GlaxoSmithKline (GSK +0.6%), Johnson & Johnson (JNJ +0.6%), Eli Lilly (LLY +0.7%), Merck (MRK), Novartis (NVS +0.7%), Pfizer (PFE +0.6%), Teva Pharmaceutical Industries (TEVA +6.4%), Amgen (AMGN +0.9%), Biogen (BIIB +3.1%), Gilead Sciences (GILD +1%), Vertex Pharmaceuticals (VRTX +0.3%) ETFs: (XPH +3.4%), (XBI +0.9%), (IBB +0.9%), (PJP +1.2%), (IHE +2.3%), (PPH +0.6%), (XLV +0.1%)
2019-06-26T00:00:00
2019-06-26T00:00:00
166.720001
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
173.009995
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
167.75
173.509995
172.839996
172
170.630005
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
2019-06-26
VRTX
Healthcare stocks under pressure ahead of Dem debate
Medical stocks are largely in the red in early trade, extending their near-term selloff ahead to tonight's first debate between Democratic presidential hopefuls in Miami. All have proposed various schemes for extending healthcare coverage and corralling drug price increases. Selected tickers: Health Care Select Sector SPDR ETF (XLV -1.2%), Vanguard Health Care ETF (VHT -1.3%), Abbott (ABT -1.3%), AstraZeneca (AZN -1.3%), Bristol-Myers Squibb (BMY -0.8%), GlaxoSmithKline (GSK -1%), Johnson & Johnson (JNJ -2%), Eli Lilly (LLY -2.9%), Novo Nordisk (NVO -0.5%), Novartis (NVS -1.2%), Pfizer (PFE -1.5%), Amgen (AMGN -0.5%), Biogen (BIIB -1.5%), Gilead Sciences (GILD -2%), Vertex Pharmaceuticals (VRTX -0.9%), Nektar Therapeutics (NKTR -3.3%), Regeneron Pharmaceuticals (REGN -1.9%), Incyte (INCY -1.5%), Sage Therapeutics (SAGE -1.2%), UnitedHealth Group (UNH -1.1%), Cardinal Health (CAH -0.2%), McKesson (MCK -1.2%), AmerisourceBergen (ABC -0.6%), Tenet Healthcare (THC -1.8%), HCA (HCA -1.5%), Humana (HUM -0.2%)
2019-06-27T00:00:00
2019-06-27T00:00:00
166.880005
170.229996
168.729996
165.729996
169.119995
172.369995
173.009995
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
167.75
173.509995
172.839996
172
170.630005
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
2019-07-08
VRTX
Biotechs and biopharmas under pressure ahead of Trump order on drug prices
Biopharma and biotech players are mostly in the red (again) ahead of an expected executive order from President Trump aimed at corralling U.S. drug prices. Specifically, the order will contain a "favored nation" clause that will be the basis for Medicare reimbursement, i.e., the reimbursement rates will match those in the country paying the lowest prices instead of an index of drug prices from around the world. Pushback from manufacturers should be substantial. The fireworks will, no doubt, be good theatre. ETFs: BIB, GRX, THW, BME, BIS, IXJ, ARKG, CHNA, IDNA, XLV, XBI, PJP Selected tickers: Amgen (AMGN -2.5%), Biogen (BIIB -2.1%), Gilead Sciences (GILD -2.5%), Vertex Pharmaceuticals (VRTX -1.7%), Merck (MRK -2.2%), Eli Lilly (LLY -1.4%), Bristol-Myers Squibb (BMY -1.1%), Pfizer (PFE -1.7%), Novartis (NVS +0.3%), Roche (OTCQX:RHHBY -0.7%), AbbVie (ABBV -2.5%), Bausch Health Companies (BHC -2%), Teva Pharmaceutical Industries (TEVA -2.3%), AstraZeneca (AZN -0.5%), GlaxoSmithKline (GSK -0.5%), Johnson & Johnson (JNJ +0.1%), Takeda (TAK -0.6%), Allergan (AGN -1.3%)
2019-07-09T00:00:00
2019-07-09T00:00:00
171.770004
172.759995
166.550003
170.259995
166.179993
166.639999
171.270004
173.270004
167.75
173.509995
172.839996
172
170.630005
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
174.080002
175.240005
173.339996
169.559998
166.830002
166.229996
169.539993
2019-07-22
VRTX
Vertex files U.S. application for triplet CF regimen VX-445
Vertex Pharmaceuticals (NASDAQ:VRTX) has submitted a marketing application to the FDA seeking approval for VX-445 (elexacaftor, tezacaftor and ivacaftor) for the potential treatment of cystic fibrosis (CF) patients at least 12 years old with one F508del mutation and one minimal function mutation or two F508del mutations. The company has requested Priority Review which, if granted, will shorten the review clock to eight months from the time of submission from 12 months.
2019-07-23T00:00:00
2019-07-23T00:00:00
172.839996
172
170.630005
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
174.080002
175.240005
173.339996
169.559998
166.830002
166.229996
169.539993
166.619995
179.289993
178.389999
175.559998
176.940002
175.649994
182.940002
182.979996
179.839996
183.910004
2019-07-25
VRTX
Dosing underway in mid-stage CF study of Proteostasis combo therapies
The first patient has been dosed in a Phase 2 clinical trial evaluating Proteostasis Therapeutics' (PTI -1.6%) doublet therapy (PTI-808 and PTI-801) and triplet therapy (doublet + PTI-428) in up to 30 F508del homozygous cystic fibrosis (CF) patients and up to 30 F508del heterozygous CF patients. PTI-808 is a potentiator, PTI-801 is a CFTR corrector and PT428 is a CFTR amplifier. Preliminary data should be available in Q1 2020. CF-related tickers: Vertex Pharmaceuticals (VRTX -1.6%), AzurRx BioPharma (AZRX), Eloxx Pharmaceuticals (ELOX -1.8%)
2019-07-26T00:00:00
2019-07-26T00:00:00
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
174.080002
175.240005
173.339996
169.559998
166.830002
166.229996
169.539993
166.619995
179.289993
178.389999
175.559998
176.940002
175.649994
182.940002
182.979996
179.839996
183.910004
179.529999
181.119995
184.940002
2019-07-25
VRTX
Vertex sets CEO transition April 1
Vertex Pharmaceuticals (NASDAQ:VRTX) announces that, on April 1, 2020, Chairman, President & CEO Jeffrey Leiden will transition to Executive Chairman while Chief Medical Officer Reshma Kewalramani, M.D. will succeed him as President & CEO.
2019-07-26T00:00:00
2019-07-26T00:00:00
168.889999
170.220001
173.779999
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
174.080002
175.240005
173.339996
169.559998
166.830002
166.229996
169.539993
166.619995
179.289993
178.389999
175.559998
176.940002
175.649994
182.940002
182.979996
179.839996
183.910004
179.529999
181.119995
184.940002
2019-07-30
VRTX
Vertex Pharmaceuticals Q2 2019 Earnings Preview
Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q2 earnings results on Wednesday, July 31st, after market close. The consensus EPS Estimate is $1.07 (+13.8% Y/Y) and the consensus Revenue Estimate is $884.66M (+17.6% Y/Y). Over the last 2 years, vrtx has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time. Over the last 3 months, EPS estimates have seen 12 upward revisions and 6 downward. Revenue estimates have seen 8 upward revisions and 4 downward.
2019-07-31T00:00:00
2019-07-31T00:00:00
177.940002
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
174.080002
175.240005
173.339996
169.559998
166.830002
166.229996
169.539993
166.619995
179.289993
178.389999
175.559998
176.940002
175.649994
182.940002
182.979996
179.839996
183.910004
179.529999
181.119995
184.940002
187.089996
183.720001
186.399994
2019-07-31
VRTX
Vertex Pharma up 2% after hours on Q2 beat, guidance raise
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 results ($M): Revenues: 941.3 (+25.1%); product sales: 940.4 (+25.4%). Key product sales: Symdeko/Symkevi: 362 (+94.6%); Orkambi: 316 (+69.9%); Kalydeco: 262 (+3.6%). Net income: 267.4 (+28.9%); non-GAAP net income: 327.3 (+34.1%); EPS: 1.03 (+28.8%) non-GAAP EPS: 1.26 (+34.0%). 2019 guidance: Product sales: $3.60B - 3.70B from $3.45B - 3.55B. Shares up 2% after hours. Previously: Vertex Pharmaceuticals EPS beats by $0.19, beats on revenue (July 31)
2019-08-01T00:00:00
2019-08-01T00:00:00
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
174.080002
175.240005
173.339996
169.559998
166.830002
166.229996
169.539993
166.619995
179.289993
178.389999
175.559998
176.940002
175.649994
182.940002
182.979996
179.839996
183.910004
179.529999
181.119995
184.940002
187.089996
183.720001
186.399994
184.210007
2019-07-31
VRTX
Vertex Pharmaceuticals EPS beats by $0.19, beats on revenue
Vertex Pharmaceuticals (NASDAQ:VRTX): Q2 Non-GAAP EPS of $1.26 beats by $0.19; GAAP EPS of $1.03 beats by $0.27. Revenue of $941.3M (+25.5% Y/Y) beats by $56.64M. Shares -1.7%. Press Release
2019-08-01T00:00:00
2019-08-01T00:00:00
181.75
182.169998
183.970001
181.020004
180.149994
177.660004
178.580002
183.380005
181.839996
179.529999
183.259995
178.339996
176.75
178.460007
178.759995
176.009995
175.789993
176.369995
176.160004
177.139999
178.089996
174.130005
174.080002
175.240005
173.339996
169.559998
166.830002
166.229996
169.539993
166.619995
179.289993
178.389999
175.559998
176.940002
175.649994
182.940002
182.979996
179.839996
183.910004
179.529999
181.119995
184.940002
187.089996
183.720001
186.399994
184.210007